THE DURATION OF FIRST COMPLETE REMISSION OF DIFFUSE LARGE B CELL LYMPHOMA COMPARED TO NONGCB, MUM1/IRF4, AND EXPRESSION OF BCLXL AND KI67 IN IMMUNOCHEMOTHERAPY ERA
(Abstract release date: 05/19/16)
EHA Library. Sofo Hafizovic A. 06/09/16; 134954; PB2054
Dr. Alma Sofo Hafizovic
Contributions
Contributions
Abstract
Abstract: PB2054
Type: Publication Only
Background
The cell has developed mechanisms for maintaining haemostasis. Apoptosis with its internal and external signalling pathways is one of those mechanisms.
Aims
To determine the impact of immune phenotype and oncogene characteristics on the duration of first complete remission with DLBCL
Methods
Study was retrospective-prospective. 60 patients were analysed with de novo DLBCL were treated and followed in Clinical Center University of Sarajevo. Follow up median was 47 months (3-91). Patients were divided into two groups: GCB and nonGCB. In the first line of treatment all patients received immunochemotherapy R-CHOP. Biopsy material was analysed for: CD20, bcl-6, CD10, MUM1/IRF4, bcl2, bclxl, bax, bad and bid. Statistics: spearman's analysis was used where p<0.05 was considered significant.
Results
Significantly positive correlation in the group IPI>2 was found with respect to bclxl expression p=0.044 and IPI>2 with respect to expression of Ki67 ≥ 50% p=0.035. Clinical stage III / IV has a significant negative impact on the duration of CR1 in the total group, p=0.005 and the group Ki67 ≥ 50% p=0.009. Duration of CR1 in the entire group had negative correlation when compared to MUM/IRF4 with p = 0.024 and bclxl with p=0.013. Duration of CR1 is in negative correlation to the group nonGCB p=0.03 and Ki67 ≥ 50%, p=0.001.
Conclusion
found a significant negative correlation between the duration of first complete remission of DLBCL compared to nonGCB expression MUM1/IRF4, bclxl and Ki67.
Session topic: E-poster
Keyword(s): BCL2, DLBCL, Ki-67
Type: Publication Only
Background
The cell has developed mechanisms for maintaining haemostasis. Apoptosis with its internal and external signalling pathways is one of those mechanisms.
Aims
To determine the impact of immune phenotype and oncogene characteristics on the duration of first complete remission with DLBCL
Methods
Study was retrospective-prospective. 60 patients were analysed with de novo DLBCL were treated and followed in Clinical Center University of Sarajevo. Follow up median was 47 months (3-91). Patients were divided into two groups: GCB and nonGCB. In the first line of treatment all patients received immunochemotherapy R-CHOP. Biopsy material was analysed for: CD20, bcl-6, CD10, MUM1/IRF4, bcl2, bclxl, bax, bad and bid. Statistics: spearman's analysis was used where p<0.05 was considered significant.
Results
Significantly positive correlation in the group IPI>2 was found with respect to bclxl expression p=0.044 and IPI>2 with respect to expression of Ki67 ≥ 50% p=0.035. Clinical stage III / IV has a significant negative impact on the duration of CR1 in the total group, p=0.005 and the group Ki67 ≥ 50% p=0.009. Duration of CR1 in the entire group had negative correlation when compared to MUM/IRF4 with p = 0.024 and bclxl with p=0.013. Duration of CR1 is in negative correlation to the group nonGCB p=0.03 and Ki67 ≥ 50%, p=0.001.
Conclusion
found a significant negative correlation between the duration of first complete remission of DLBCL compared to nonGCB expression MUM1/IRF4, bclxl and Ki67.
Session topic: E-poster
Keyword(s): BCL2, DLBCL, Ki-67
Abstract: PB2054
Type: Publication Only
Background
The cell has developed mechanisms for maintaining haemostasis. Apoptosis with its internal and external signalling pathways is one of those mechanisms.
Aims
To determine the impact of immune phenotype and oncogene characteristics on the duration of first complete remission with DLBCL
Methods
Study was retrospective-prospective. 60 patients were analysed with de novo DLBCL were treated and followed in Clinical Center University of Sarajevo. Follow up median was 47 months (3-91). Patients were divided into two groups: GCB and nonGCB. In the first line of treatment all patients received immunochemotherapy R-CHOP. Biopsy material was analysed for: CD20, bcl-6, CD10, MUM1/IRF4, bcl2, bclxl, bax, bad and bid. Statistics: spearman's analysis was used where p<0.05 was considered significant.
Results
Significantly positive correlation in the group IPI>2 was found with respect to bclxl expression p=0.044 and IPI>2 with respect to expression of Ki67 ≥ 50% p=0.035. Clinical stage III / IV has a significant negative impact on the duration of CR1 in the total group, p=0.005 and the group Ki67 ≥ 50% p=0.009. Duration of CR1 in the entire group had negative correlation when compared to MUM/IRF4 with p = 0.024 and bclxl with p=0.013. Duration of CR1 is in negative correlation to the group nonGCB p=0.03 and Ki67 ≥ 50%, p=0.001.
Conclusion
found a significant negative correlation between the duration of first complete remission of DLBCL compared to nonGCB expression MUM1/IRF4, bclxl and Ki67.
Session topic: E-poster
Keyword(s): BCL2, DLBCL, Ki-67
Type: Publication Only
Background
The cell has developed mechanisms for maintaining haemostasis. Apoptosis with its internal and external signalling pathways is one of those mechanisms.
Aims
To determine the impact of immune phenotype and oncogene characteristics on the duration of first complete remission with DLBCL
Methods
Study was retrospective-prospective. 60 patients were analysed with de novo DLBCL were treated and followed in Clinical Center University of Sarajevo. Follow up median was 47 months (3-91). Patients were divided into two groups: GCB and nonGCB. In the first line of treatment all patients received immunochemotherapy R-CHOP. Biopsy material was analysed for: CD20, bcl-6, CD10, MUM1/IRF4, bcl2, bclxl, bax, bad and bid. Statistics: spearman's analysis was used where p<0.05 was considered significant.
Results
Significantly positive correlation in the group IPI>2 was found with respect to bclxl expression p=0.044 and IPI>2 with respect to expression of Ki67 ≥ 50% p=0.035. Clinical stage III / IV has a significant negative impact on the duration of CR1 in the total group, p=0.005 and the group Ki67 ≥ 50% p=0.009. Duration of CR1 in the entire group had negative correlation when compared to MUM/IRF4 with p = 0.024 and bclxl with p=0.013. Duration of CR1 is in negative correlation to the group nonGCB p=0.03 and Ki67 ≥ 50%, p=0.001.
Conclusion
found a significant negative correlation between the duration of first complete remission of DLBCL compared to nonGCB expression MUM1/IRF4, bclxl and Ki67.
Session topic: E-poster
Keyword(s): BCL2, DLBCL, Ki-67
{{ help_message }}
{{filter}}